69 related articles for article (PubMed ID: 9476930)
21. ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
Nakajo M; Kajiya Y; Tani A; Yoneda S; Shirahama H; Higashi M; Nakajo M
Eur J Radiol; 2012 Jan; 81(1):146-51. PubMed ID: 20810231
[TBL] [Abstract][Full Text] [Related]
22. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
[TBL] [Abstract][Full Text] [Related]
23. Parametric Imaging of Biologic Activity of Atherosclerosis Using Dynamic Whole-Body Positron Emission Tomography.
Derlin T; Werner RA; Weiberg D; Derlin K; Bengel FM
JACC Cardiovasc Imaging; 2022 Dec; 15(12):2098-2108. PubMed ID: 36481078
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
[TBL] [Abstract][Full Text] [Related]
25. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
26. Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas.
Skamene SR; Rakheja R; Dahlstrom KR; Roberge D; Nahal A; Charest M; Turcotte R; Hickeson M; Freeman C
J Surg Oncol; 2014 Apr; 109(5):410-4. PubMed ID: 24310279
[TBL] [Abstract][Full Text] [Related]
27. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma.
Higashi K; Ueda Y; Seki H; Yuasa K; Oguchi M; Noguchi T; Taniguchi M; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jun; 39(6):1016-20. PubMed ID: 9627336
[TBL] [Abstract][Full Text] [Related]
28. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
[TBL] [Abstract][Full Text] [Related]
29. Clinical validation of a population-based input function for 20-min dynamic whole-body
Dias AH; Smith AM; Shah V; Pigg D; Gormsen LC; Munk OL
EJNMMI Phys; 2022 Sep; 9(1):60. PubMed ID: 36076097
[TBL] [Abstract][Full Text] [Related]
30. A statistical measure of tissue heterogeneity with application to 3D PET sarcoma data.
O'Sullivan F; Roy S; Eary J
Biostatistics; 2003 Jul; 4(3):433-48. PubMed ID: 12925510
[TBL] [Abstract][Full Text] [Related]
31. Avid F-18 FDG uptake in prostatic sarcoma.
Minamimoto R; Tateishi U; Uemira H; Yamanaka S; Kubota Y; Inoue T
Clin Nucl Med; 2009 Jun; 34(6):388-9. PubMed ID: 19487855
[No Abstract] [Full Text] [Related]
32. PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.
Pantel AR; Bae SW; Li EJ; O'Brien SR; Manning HC
Cancer J; 2024 May-Jun 01; 30(3):159-169. PubMed ID: 38753750
[TBL] [Abstract][Full Text] [Related]
33. Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study.
Crombé A; Bertolo F; Vanhersecke L; Guegan JP; Bessede A; Perret R; Le Loarer F; Chaire V; Coindre JM; Lucchesi C; Italiano A
Biomark Res; 2024 Jan; 12(1):3. PubMed ID: 38185642
[TBL] [Abstract][Full Text] [Related]
34. Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).
Sunassee ED; Jardim-Perassi BV; Madonna MC; Ordway B; Ramanujam N
Mol Cancer Res; 2023 Oct; 21(10):995-1009. PubMed ID: 37343066
[TBL] [Abstract][Full Text] [Related]
35. Kinetic analysis and optimisation of
Malaspina S; Oikonen V; Kuisma A; Ettala O; Mattila K; Boström PJ; Minn H; Kalliokoski K; Postema EJ; Miller MP; Scheinin M
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3723-3731. PubMed ID: 33846844
[TBL] [Abstract][Full Text] [Related]
36. Preclinical PET tracers for the evaluation of sarcomas: understanding tumor biology.
Sigal IR; Sebro R
Am J Nucl Med Mol Imaging; 2018; 8(6):428-440. PubMed ID: 30697463
[TBL] [Abstract][Full Text] [Related]
37. Near-simultaneous quantification of glucose uptake, mitochondrial membrane potential, and vascular parameters in murine flank tumors using quantitative diffuse reflectance and fluorescence spectroscopy.
Zhu C; Martin HL; Crouch BT; Martinez AF; Li M; Palmer GM; Dewhirst MW; Ramanujam N
Biomed Opt Express; 2018 Jul; 9(7):3399-3412. PubMed ID: 29984105
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.
Chen L; Wu X; Ma X; Guo L; Zhu C; Li Q
Medicine (Baltimore); 2017 Feb; 96(6):e5913. PubMed ID: 28178131
[TBL] [Abstract][Full Text] [Related]
39. Review of Osteosarcoma and Current Management.
Durfee RA; Mohammed M; Luu HH
Rheumatol Ther; 2016 Dec; 3(2):221-243. PubMed ID: 27761754
[TBL] [Abstract][Full Text] [Related]
40. Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET.
Karakatsanis NA; Zhou Y; Lodge MA; Casey ME; Wahl RL; Zaidi H; Rahmim A
Phys Med Biol; 2015 Nov; 60(22):8643-73. PubMed ID: 26509251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
